0001104659-20-094751.txt : 20200813 0001104659-20-094751.hdr.sgml : 20200813 20200813170136 ACCESSION NUMBER: 0001104659-20-094751 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20200811 FILED AS OF DATE: 20200813 DATE AS OF CHANGE: 20200813 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Naos Yaron CENTRAL INDEX KEY: 0001742727 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33357 FILM NUMBER: 201100109 MAIL ADDRESS: STREET 1: 2 SNUNIT STREET STREET 2: SCIENCE PARK, POB 455 CITY: CARMIEL STATE: L3 ZIP: 20100 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Protalix BioTherapeutics, Inc. CENTRAL INDEX KEY: 0001006281 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 650643773 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 SNUNIT ST STREET 2: SCIENCE PARK, POB 455 CITY: CARMIEL STATE: L3 ZIP: 2161401 BUSINESS PHONE: 972-4-988-9488 MAIL ADDRESS: STREET 1: 2 SNUNIT ST STREET 2: SCIENCE PARK, POB 455 CITY: CARMIEL STATE: L3 ZIP: 2161401 FORMER COMPANY: FORMER CONFORMED NAME: ORTHODONTIX INC DATE OF NAME CHANGE: 19980422 FORMER COMPANY: FORMER CONFORMED NAME: EMBASSY ACQUISITION CORP DATE OF NAME CHANGE: 19960124 4 1 tm2027548d1_4.xml OWNERSHIP DOCUMENT X0306 4 2020-08-11 0 0001006281 Protalix BioTherapeutics, Inc. PLX 0001742727 Naos Yaron C/O PROTALIX BIOTHERAPEUTICS, INC. 2 SNUNIT STREET, SCIENCE PARK, POB 455 CARMIEL L3 2161401 ISRAEL 0 1 0 0 Sr. VP, Operations Stock Options (Right to Buy) 3.59 2020-08-11 4 A 0 122656 0 A 2030-08-11 Common Stock 122656 122656 D The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended. Does not include (i) options to purchase 5,000 shares of common stock at an exercise price equal to $17.20 per share that expire on March 23, 2025 and (ii) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028. /s/ Joseph R. Magnas, POA 2020-08-13 EX-24 2 tm2027548d1_ex24.htm EXHIBIT 24

 

Exhibit 24

 

POWER OF ATTORNEY

 

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Dror Bashan, Eyal Rubin and Joseph R. Magnas the undersigned’s true and lawful attorney-in-fact to: (i) execute for and on behalf of the undersigned, Forms ID, 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended and the rules thereunder in connection with the undersigned’s holdings of and transactions in securities issued by Protalix BioTherapeutics, Inc., a Delaware corporation (the “Company”); (ii) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5 and timely file such form with the U.S. Securities and Exchange Commission and any required stock exchange or similar authority, including the NYSE American and (iii) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

 

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

 

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

 

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of August 13, 2020.

 

/s/ Yaron Naos

  
Name: Yaron Naos